Loganic acid

Loganic acid is an iridoid isolated from cornelian cherry fruits. Loganic acid inhibits NF-κB signaling pathway, activates Nrf2 signaling pathway, exhibits anti-inflammatory activity. Loganic acid can modulate diet-induced atherosclerosis and redox status. Loganic acid has strong free radical scavenging activity and remarkable cyto-protective effect against heavy metal mediated toxicity. Loganic acid is orally active^[1][2][3][4]. In Vitro:Loganic acid exhibits antioxidant activity, scavenges DPPH free radicals, superoxide anion free radicals, and hydroxyl free radicals with IC₅₀s of 149 μg/mL, 632.43 μg/mL and 29.78 μg/mL, respectively^[2].
Loganic acid (100 μg/mL, 24 h) prevents heavy metal-induced cytotoxicity in PBMC, inhibits HgCl₂-induced ROS generation and lipid peroxidation^[2].
Loganic acid (0-50 µM, 5 days) activates alkaline phosphatase (ALP), promotes the osteoblast differentiation and inhibits the osteoclast differentiation^[3].
Loganic acid (0-50 µM, 24 h) inhibits NF-κB nuclear translocation, activates Nrf2 translocation, and reduces the expressions of proinflammatory cytokine (IL-1β, IL-6, TNF-α) in LPS (HY-D1056)-stimulated RAW264.7 cell^[4]. In Vivo:Loganic acid (20 mg/kg, po, daily for 60 days) exhibits anti-oxidation and anti-atherosclerosis activities in rabbit hypercholesterolemia models^[1].
Loganic acid (2-50 mg/kg, po, once daily for 12 weeks) prevents OVX-induced bone loss and increases bone mineral density in OVX-induced osteoporosis mouse model^[3].
Loganic acid (15-30 mg/kg, po, once daily for 14 days) ameliorates DSS (HY-116282C)-induced ulcerative colitis in mouse models^[4].